Current Month 2005
Article Features
  Revised Classification System is Effective for Predicting Breast Cancer Outcome in Some Patients
BRCA1 Tumor Suppression Nullified by Cyclin D1 at the Estrogen Receptor
Fertility Issues Not Discussed with Many Younger Breast Cancer Patients
Patient's Genes Can Predict Response to Chemotherapy for Breast Cancer
Researchers Identify Gene Set Linked to Breast Cancer Spread to Lungs
Scientists Discover Genetic Pathway Responsible for Breast Cancer Cell Growth
Blood Test May Identify Multiple Markers for Breast and Ovarian Cancer
Scientists Develop Nanotech-Laser Treatment That Kills Cancer Cells Without Harming Healthy Tissue
Educational and Nutritional Programs Improve the Well-Being of Breast Cancer Survivors
Obesity Lowers Likelihood of Receiving Preventive Health Care
Method of Breast Cancer Detection May Be Prognostic Factor
Improved Breast Cancer Survival Rates Linked to Diagnosing Smaller Tumors
Researchers Discover New Tumor Defense System
Weight Loss Decreases Risk of Breast Cancer in Susceptible Women
Many Choose More Aggressive Breast Cancer Surgery Despite Breast Sparing Option


Stage of Tumor After Neoadjuvant Chemotherapy for Breast Cancer Associated With Survival

The stage of the tumor left after neoadjuvant chemotherapy for breast cancer - as determined by the revised American Joint Committee on Cancer (AJCC) tumor-node-metastasis staging system - is associated with both distant disease-free survival and overall survival, according to a new study.

In breast cancer, the extent of tumor left behind after neoadjuvant chemotherapy is an established intermediate endpoint for relapse and survival. In January 2003, the AJCC modified their tumor-node-metastasis staging system. To determine whether this new system is able to predict patient survival after neoadjuvant chemotherapy for breast cancer, Lisa A. Carey, M.D., of the University of North Carolina at Chapel Hill, and colleagues assessed the stage of the residual tumor in 132 patients with nonmetastatic breast cancer after they had undergone neoadjuvant chemotherapy. The patients were then followed for a median of 5 years.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon